PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026European Journal of Heart Failure0 citations

Balancing complexity and throughput: a step-wise self-assembly approach for reproducible cardiovascular organoids

View Full Paper
MMM MosheNKNoam KazmaIHIdan Refael Haim

Key Points

  • To create reproducible, ring-shaped, multicellular human cardiac organoids that balance complexity with functional contractility.
  • Utilized a step-wise autonomous self-assembly (SASA) protocol for organoid engineering.
  • Generated organoids from hiPSC-derived cardiomyocytes and cardiac fibroblasts.
  • Applied contactless optogenetic pacing for contraction control.
  • Compared SASA method with a one-step bicellular seeding approach.
  • Assessed organoid function using motion analysis and fluorescent staining.
  • SASA organoids had greater sarcomere length (1.85 µm) compared to one-step organoids (1.72 µm, p < 0.0006).
  • Improved contraction force was observed in SASA organoids (0.431 mN/mm²) vs one-step (0.136 mN/mm², p < 0.0001).
  • SASA organoids showed enhanced functional responses to inotropic agents.
  • Structural homogeneity and tissue morphology were significantly better in SASA organoids.

Abstract

Abstract The rise of induced pluripotent stem cell (iPSC) technology has revolutionized disease modeling and cardiovascular regeneration. For clinical applications like drug discovery and toxicity screening, organoids must achieve essential complexity—multicellularity, maturation, and functional force generation. While spherical unicellular organoids enable high throughput, their lack of cellular diversity and poor reproducibility limit their relevance for these purposes. More complex multicellular organoids offer greater physiological fidelity but require costly, labor-intensive methods. This presents a major challenge: balancing the need for organoid complexity with the high throughput required for clinical use. This research aims to create reproducible, ring-shaped, multicellular human cardiac organoids that combine structural complexity with functional contractility. The engineered tissues promote cell alignment, enhance physiological relevance, and optimize nutrient diffusion, enabling high-throughput modeling of cardiomyopathies and testing of therapeutic interventions. Ring-shaped, multicellular cardiac organoids were generated from hiPSC-derived cardiomyocytes and cardiac fibroblasts using a step-wise autonomous self-assembly (SASA) protocol, in which fibroblasts were seeded prior to cardiomyocytes to promote extracellular matrix deposition and tissue maturation. Contactless optogenetic pacing controlled contraction frequency, fluorescent staining assessed sarcomere alignment and organization, and video-based motion analysis quantified contraction force and relaxation kinetics. Two organoid engineering strategies were compared: the Step-wise Autonomous Self-assembly (SASA) method and a one-step bicellular seeding approach. The SASA method yielded organoids with significantly improved structural homogeneity, cell survival, and tissue morphology. Sarcomere length was greater in SASA organoids (1.85 µm) than in one-step organoids (1.72 µm, p 0.0006). Moreover, sarcomere alignment was more consistent, with a lower angular dispersion indicating enhanced structural anisotropy (p 0.0001). Under 1 Hz contactless optogenetic pacing, SASA organoids showed higher contraction force (0.431 mN/mm²) compared to one-step organoids (0.136 mN/mm², p 0.0001). To assess tissue relevance, SASA organoids responded to inotropic agents as expected: 0.5 µM Isoproterenol increased beating frequency (~0.9 → 1.3 Hz) and contraction stress (0.594 → 0.841 mN/mm², p 0.0001), while 0.9 µM Mavacamten reduced contraction stress (0.606 → 0.300 mN/mm², p 0.0001). The initial results demonstrate that the SASA approach, with contactless optogenetic pacing, generates reproducible cardiac organoids with enhanced homogeneity, survival, and contractile function. By balancing complexity and scalability, this platform provides a robust, high-throughput model for drug testing and disease modeling, improving translational relevance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Moshe et al. (2026) studied this question.

synapsesocial.com/papers/69b64c67b42794e3e660dabdhttps://doi.org/10.1093/ejhf/xuag034.047
Ask AI
Helpful
Bookmark
Share
View Full Paper